查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417546

地中海貧血治療市場報告：至2030年的趨勢、預測與競爭分析

Thalassemia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

地中海貧血治療的趨勢和預測

2030年，全球地中海貧血治療市場預計將達到122億美元，2024年至2030年的年複合成長率為5.1%。該市場的主要促進因素是地中海貧血盛行率的增加、開發的地中海貧血療法數量的增加以及藥物研發和醫療保健成本的增加。全球地中海貧血治療市場的未來充滿希望，醫院/診所和診斷實驗室市場充滿機會。

地中海貧血治療市場洞察

Lucintel 預測，由於徹底血液篩檢的風險較低，輸血將在預測期內達到最高成長。

由於人們對地中海貧血的認知不斷提高以及政府試圖鼓勵基因治療，北美在預測期內仍將是最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，全球地中海貧血治療市場預計將達到 122 億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球地中海貧血治療市場預計將以5.1%的年複合成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要驅動力是地中海貧血盛行率的增加、開發的地中海貧血藥物數量的增加以及藥物研發和醫療保健成本的增加。

Q4.市場的主要細分市場是什麼？

A4.全球地中海貧血治療市場的未來看起來充滿希望，醫院/診所和診斷實驗室市場存在機會。

Q5.市場上主要企業有哪些？

A5.主要的地中海貧血治療公司如下。

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於徹底血液篩檢的風險較低，輸血將在預測期內出現最高成長。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於人們對地中海貧血的認知不斷提高以及政府試圖鼓勵基因治療，北美在預測期內仍將是最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球地中海貧血治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球地中海貧血治療市場趨勢（2018-2023）與預測（2024-2030）
  • 依類型分類的全球地中海貧血治療市場
    • Alpha地中海貧血
    • Beta地中海型貧血
  • 依治療分類的全球地中海貧血治療市場
    • 輸血
    • 鐵螯合療法
    • 補充品葉酸
    • 基因治療
    • 骨髓移植
  • 依最終用途分類的全球地中海貧血治療市場
    • 醫院和診所
    • 診斷實驗室
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球地中海貧血治療市場（依地區）
  • 北美地中海貧血治療市場
  • 歐洲地中海貧血治療市場
  • 亞太地區地中海貧血治療市場
  • 其他地區地中海貧血治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球地中海貧血治療市場成長機會（依類型）
    • 全球地中海貧血治療市場成長機會（依治療）
    • 全球地中海貧血治療市場成長機會（依最終用途）
    • 全球地中海貧血治療市場成長機會（依地區）
  • 全球地中海貧血治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球地中海貧血治療市場的產能擴張
    • 全球地中海貧血治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell
簡介目錄

Thalassemia Treatment Trends and Forecast

The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets. The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.

A more than 150-page report is developed to help in your business decisions.

Thalassemia Treatment by Segment

The study includes a forecast for the global thalassemia treatment by type, treatment, end use, and region.

Thalassemia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Alpha-Thalassemia
  • Beta Thalassemia

Thalassemia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Transfusions
  • Iron Chelation Therapy
  • Folic Acid Supplements
  • Gene Therapy
  • Bone Marrow Transplants

Thalassemia Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital and Clinics
  • Diagnostic Laboratories
  • Others

Thalassemia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Thalassemia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies thalassemia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the thalassemia treatment companies profiled in this report include-

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Thalassemia Treatment Market Insights

Lucintel forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.

North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.

Features of the Global Thalassemia Treatment Market

Market Size Estimates: Thalassemia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Thalassemia treatment market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Thalassemia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, treatment, end use, and regions for the thalassemia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the thalassemia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the thalassemia treatment market size?

Answer: The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030.

Q2. What is the growth forecast for thalassemia treatment market?

Answer: The global thalassemia treatment market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the thalassemia treatment market?

Answer: The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.

Q4. What are the major segments for thalassemia treatment market?

Answer: The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets.

Q5. Who are the key thalassemia treatment market companies?

Answer: Some of the key thalassemia treatment companies are as follows.

  • Novartis
  • Bluebird Bio
  • Kiadis Pharma
  • CELGENE
  • Sangamo Therapeutics
  • Acceleron Pharma
  • Gamida Cell

Q6. Which thalassemia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.

Q7. In thalassemia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the thalassemia treatment market by type (alpha-thalassemia and beta thalassemia), treatment (blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, and bone marrow transplants), end use (hospital and clinics, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Thalassemia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Thalassemia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Thalassemia Treatment Market by Type
    • 3.3.1: Alpha-thalassemia
    • 3.3.2: Beta Thalassemia
  • 3.4: Global Thalassemia Treatment Market by Treatment
    • 3.4.1: Blood Transfusions
    • 3.4.2: Iron Chelation Therapy
    • 3.4.3: Folic Acid Supplements
    • 3.4.4: Gene Therapy
    • 3.4.5: Bone Marrow Transplants
  • 3.5: Global Thalassemia Treatment Market by End Use
    • 3.5.1: Hospital and Clinics
    • 3.5.2: Diagnostic Laboratories
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Thalassemia Treatment Market by Region
  • 4.2: North American Thalassemia Treatment Market
    • 4.2.1: North American Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.2.2: North American Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.3: European Thalassemia Treatment Market
    • 4.3.1: European Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.3.2: European Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.4: APAC Thalassemia Treatment Market
    • 4.4.1: APAC Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.4.2: APAC Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others
  • 4.5: ROW Thalassemia Treatment Market
    • 4.5.1: ROW Thalassemia Treatment Market by Treatment: Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants
    • 4.5.2: ROW Thalassemia Treatment Market by End Use: Hospital and Clinics, Diagnostic Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Thalassemia Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Thalassemia Treatment Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Thalassemia Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Thalassemia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Thalassemia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Thalassemia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Thalassemia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Bluebird Bio
  • 7.3: Kiadis Pharma
  • 7.4: CELGENE
  • 7.5: Sangamo Therapeutics
  • 7.6: Acceleron Pharma
  • 7.7: Gamida Cell